Hereditary spastic paraparesis (HSP) comprises a large and growing group of chronic progressive neurodegenerative diseases with varying patterns of inheritance, age at onset, and disease severity. These diseases share a common affection of the corticospinal tracts. Heterozygous mutations in the N-terminal motor domain of the neuronal kinesin heavy chain gene (*KIF5A*) are associated with autosomal dominant HSP 10 (SPG10) and less commonly with Charcot-Marie-Tooth type 2, with or without pyramidal signs.^[@R1],[@R2]^ Rarely, mutations in this gene are also associated with cerebellar ataxia or cognitive impairment.^[@R2]^ In addition, a recent genome-wide association study has identified variants in the C-terminal of *KIF5A* associated with amyotrophic lateral sclerosis (ALS).^[@R3]^

*KIF5A* encodes one of 2 heavy chain subunits that together with 2 light chain subunits make up a tetrameric kinesin-1 protein.^[@R1],[@R4],[@R5]^ This kinesin is crucial for anterograde molecular axonal transport by binding to microtubule.^[@R4],[@R6]^ At least 23 mutations in *KIF5A* with HSP phenotype have been reported.^[@R1],[@R2],[@R5],[@R7],[@R8]^

In vitro assays have demonstrated that mutant forms of the kinesin-1 protein impair the transport of cargo along microtubule.^[@R6]^ Furthermore, 2 studies on cultured neurons from *Kif5A* knockout mice and mice with mutant *Kif5A* have demonstrated disturbed axonal bidirectional transport of mitochondria and neurofilaments, respectively.^[@R9],[@R10]^ Thus, in patients, *KIF5A* mutations are believed responsible for an axonopathy damaging both the central and peripheral nervous systems.^[@R1],[@R5],[@R7]^ Here, we hypothesized that patients with SPG10 would demonstrate an elevation of neurofilament light (NFL) chain in CSF.

Methods {#s1}
=======

Standard protocol approvals, registrations, and patient consents {#s1-1}
----------------------------------------------------------------

All patients have given oral and written consent to this characterization approved by the regional ethical board in Stockholm, Sweden (2016/2503-31/2).

Clinical assessments {#s1-2}
--------------------

Patients with a known diagnosis of SPG10, followed at Karolinska University Hospital, were eligible for the study. In total, 4 patients from 2 Swedish families (A and B) with heterozygous *KIF5A* mutations were included ([figure](#F1){ref-type="fig"}). Patients were assessed with standardized clinical examination that included the Spastic Paraplegia Rating Scale (SPRS), Friedreich Ataxia Rating Scale part 1: functional staging for ataxia, Inventory of Non-Ataxia Signs, Instituto de Pesquisa Clinica Evandro Chagas Scale, Scale for the Assessment and Rating of Ataxia, and Montreal Cognitive Assessment. The inclusion of rating scales assessing cerebellar function was chosen based on reports of ataxia as a feature in patients with *KIF5A* mutations and other familial kinesin motor proteinopathies.^[@R2],[@R11]^ Standardized examination took place between January and March of 2018.

![Pedigrees of the 2 Swedish families with SPG10\
Pedigrees of family A and B harboring the c.767A\>G (p.Asn256Ser) and c.967C\>T (p.Arg323Trp) mutations in *KIF5A*, respectively. Patient I:1 in family A, due to lack of comprehensive medical notes, is considered possibly symptomatic based on historical description.](NG2019010140f1){#F1}

Genetic analyses {#s1-3}
----------------

Both families were examined with targeted genetic analyses for autosomal dominant HSP (e-Methods, [links.lww.com/NXG/A160](http://links.lww.com/NXG/A160)).

Biochemical analyses {#s1-4}
--------------------

CSF was collected from 3 patients (III:1 in family A and II:1, III:1 in family B) by standard procedures. Patient II:1, in family A, declined lumbar puncture. For patient III:1, in family A, CSF had been collected in 2012 and since then stored at −80°C. Levels of the neurodegenerative markers total tau (t-tau), phosphorylated tau (p-tau), β-amyloid 42/40 (Aβ42/40) ratio, and NFL chain and monoamine metabolites homovanillic acid (HVA), 5-hydroxyindoleacetic acid (5-HIAA) and 3-methoxy-4-hydroxyphenylglycol (MHPG) were determined (e-Methods, [links.lww.com/NXG/A160](http://links.lww.com/NXG/A160)).

Electrophysiology {#s1-5}
-----------------

Motor and sensory nerve conduction studies were compiled from all 4 patients including, at a minimum, unilateral assessment of the median, peroneal, tibial, and sural nerves. Nerve conduction studies were conducted with Natus, Viking EDX (Cephalon A/S; Denmark). Quantitative sensory testing, detecting perception thresholds for cold and heat, was assessed bilaterally in the lateral foot and unilaterally in the hand with Medusa, TSA II (Cephalon A/S; Denmark).

Neuroimaging {#s1-6}
------------

Historic data from brain and spinal cord MRI were compiled and reviewed.

Data availability statement {#s1-7}
---------------------------

Anonymized data will be shared by request from any qualified investigator.

Results {#s3}
=======

The previously reported heterozygous mutations in *KIF5A*, c.767A\>G (p.Asn256Ser) and c.967C\>T (p.Arg323Trp) were found in family A and B, respectively.^[@R1],[@R5]^ Briefly, all the affected patients presented with a variable degree of spastic paraparesis, which is in line with previous descriptions.^[@R1],[@R2],[@R5],[@R7],[@R8]^ Onset was at adult age in all but one case (III:1 in family B), in which the onset was insidious during childhood. All patients had variable degrees of polyneuropathy (PNP). The index case in family B reported neuropathic symptoms many years after onset of paraparesis, and electrodiagnostic testing demonstrated a moderate axonal sensorimotor PNP. The historical rate of overall clinical progression was slow in both families. We did not find evidence of cerebellar ataxia, psychiatric symptoms, or cognitive impairment. None of the patients were treated with psychotropic medications. Neuroimaging was normal. A summary of clinical, radiologic, and electrodiagnostic characteristics for both families is shown in [table 1](#T1){ref-type="table"}.

###### 

Electrodiagnostic, neuroradiologic, genetic, and clinical features of 2 families with SPG10

![](NG2019010140t1)

CSF-NFL was elevated only in the patient with the longest disease duration. In addition, and more unexpected, we found in all tested patients elevated CSF-HVA levels, and in 2 patients, CSF-MHPG was reduced. The serotonin metabolite (5-HIAA), Aβ42/40 ratio, and t-tau and p-tau levels were normal. Results from CSF analyses are presented in [table 2](#T2){ref-type="table"}. Detailed case descriptions are included in the supplemental data (e-Clinical phenotypes, [links.lww.com/NXG/A161](http://links.lww.com/NXG/A161)).

###### 

CSF profiles of 3 patients with SPG10

![](NG2019010140t2)

Discussion {#s4}
==========

There is a need for biomarkers and disease-modifying treatments for HSP diseases. The reasons for intrafamilial phenotype variability in SPG10 remain to be elucidated.^[@R1],[@R7]^ This variation is similar to what is seen in other forms of familial kinesin motor proteinopathies such as SPG30 (*KIF1A*) and SPG58 (*KIF1C*); however, these diseases are biallelic and present with a more severe phenotype than SPG10.^[@R11],[@R12]^

An impairment of axonal transport, with resulting length-dependent axonal degeneration, forms the main theory of the underlying pathophysiology in SPG10.^[@R1]^ CSF levels of NFL, an important cytoskeletal component of the axon, were mildly elevated in the patient with longest disease duration. This patient also demonstrated the highest SPRS score ([table 1](#T1){ref-type="table"}). Because mutated *KIF5A* is known to impair axonal transport of neurofilaments, at least in vitro, we were expecting a more general elevation in our patients.^[@R9]^ However, NFL elevation was not evident in the 2 younger patients why such elevation cannot be viewed as an obligate finding in SPG10. These results are in contrast with studies in ALS, where NFL has been proposed as a biomarker.^[@R13]^ Furthermore, elevated CSF levels of phosphorylated neurofilament heavy chain in patients with HSP (n = 9) compared with controls have been reported in a previous study.^[@R14]^ It will be interesting to study NFL levels in patients with ALS harboring *KIF5A* mutations.

Assuming that intact axonal transport is important to maintain synaptic supply of monoamines, we analyzed these metabolites. Surprisingly, CSF-HVA was elevated in all tested patients, of which none had a history of mood disturbance, psychotic behaviors, or treatment with psychotropic drugs. Thus, the clinical correlates of this abnormality is unclear. In addition, 2 patients had decreased levels of the noradrenergic metabolite MHPG in CSF. In keeping with the proposed pathophysiology of an underlying axonopathy in SPG10, deficiency of various neurotransmitters such as noradrenaline may either reflect impaired transportation of synaptic proteins or an epiphenomenon. Regardless, the specificity of these abnormalities remains to be explained.

Small sample size is the main limitation of this study. In addition, we cannot rule out that the prolonged CSF storage time (III:1 in family A) might have underestimated the values of t-tau and Aβ42/40 ratio.

Previous reports on the CSF profile in patients with *KIF5A* mutations are rare. Thus, future studies in larger cohorts are needed to better discern whether noradrenergic deficiency and increased dopaminergic neurotransmission are prevalent findings in SPG10, other kinesin proteinopathies, and/or patients with ALS with *KIF5A* mutations. It will also be important to delineate potential clinical correlates to these changes in monoaminergic neurotransmission.
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